133 related articles for article (PubMed ID: 23132699)
41. Multimodality treatment for gastric carcinoid tumor with liver metastases.
Caplin ME; Hodgson HJ; Dhillon AP; Begent R; Buscombe J; Dick R; Rolles K; Burroughs AK
Am J Gastroenterol; 1998 Oct; 93(10):1945-8. PubMed ID: 9772061
[TBL] [Abstract][Full Text] [Related]
42. [Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin-A for clinical follow-up].
Igaz P; Rácz K; Tulassay Z
Orv Hetil; 2007 Dec; 148(49):2343-6. PubMed ID: 18048114
[TBL] [Abstract][Full Text] [Related]
43. Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors.
Moattari AR; Deftos LJ; Vinik AI
J Clin Endocrinol Metab; 1989 Oct; 69(4):902-5. PubMed ID: 2778040
[TBL] [Abstract][Full Text] [Related]
44. Comments on "Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients".
Schran HF; Hager DF
Pancreas; 2008 Oct; 37(3):334-5; author reply 336-7. PubMed ID: 18815560
[No Abstract] [Full Text] [Related]
45. Chromogranin A as a determinant of midgut carcinoid tumour volume.
Kölby L; Bernhardt P; Swärd C; Johanson V; Ahlman H; Forssell-Aronsson E; Stridsberg M; Wängberg B; Nilsson O
Regul Pept; 2004 Aug; 120(1-3):269-73. PubMed ID: 15177946
[TBL] [Abstract][Full Text] [Related]
46. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors.
Jensen EH; Kvols L; McLoughlin JM; Lewis JM; Alvarado MD; Yeatman T; Malafa M; Shibata D
Ann Surg Oncol; 2007 Feb; 14(2):780-5. PubMed ID: 17146740
[TBL] [Abstract][Full Text] [Related]
47. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.
Al-Efraij K; Aljama MA; Kennecke HF
Cancer Med; 2015 Jun; 4(6):864-70. PubMed ID: 25727756
[TBL] [Abstract][Full Text] [Related]
48. Gastric carcinoids in patients with hypergastrinemia.
Jordan PH; Barroso A; Sweeney J
J Am Coll Surg; 2004 Oct; 199(4):552-5. PubMed ID: 15454137
[TBL] [Abstract][Full Text] [Related]
49. Gastroscopic screening for gastric carcinoids and carcinoma in pernicious anemia.
Sjöblom SM; Sipponen P; Miettinen M; Karonen SL; Jrvinen HJ
Endoscopy; 1988 Mar; 20(2):52-6. PubMed ID: 3383791
[TBL] [Abstract][Full Text] [Related]
50. Defining surgical indications for type I gastric carcinoid tumor.
Gladdy RA; Strong VE; Coit D; Allen PJ; Gerdes H; Shia J; Klimstra DS; Brennan MF; Tang LH
Ann Surg Oncol; 2009 Nov; 16(11):3154-60. PubMed ID: 19727959
[TBL] [Abstract][Full Text] [Related]
51. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
[TBL] [Abstract][Full Text] [Related]
52. [A case of rectal carcinoid with multiple liver, lymph nodes and bone metastases that responded to an octreotide therapy].
Yamashita K; Takase S; Nakamura T; Matsuda Y; Imanishi T; Sumi Y; Suzuki S; Kamigaki T; Ku Y; Kuroda D
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2349-51. PubMed ID: 21224569
[TBL] [Abstract][Full Text] [Related]
53. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
[TBL] [Abstract][Full Text] [Related]
54. Predictive value of gastrin levels for the diagnosis of gastric enterochromaffin-like cell hyperplasia in patients with Hashimoto's thyroiditis.
Nicolaou A; Thomas D; Alexandraki KI; Sougioultzis S; Tsolakis AV; Kaltsas G
Neuroendocrinology; 2014; 99(2):118-22. PubMed ID: 24776735
[TBL] [Abstract][Full Text] [Related]
55. Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors.
Curran T; Tulin-Silver S; Patel K; Ward S; Schneiderman M; Harpaz N; Schwartz M; Itzkowitz S; Warner RR; Kim MK
Pancreas; 2011 Nov; 40(8):1253-7. PubMed ID: 21975435
[TBL] [Abstract][Full Text] [Related]
56. [Gastric carcinoid tumours. Is there a place for antrectomy?].
Guillem P
Ann Chir; 2005 Jun; 130(5):323-6. PubMed ID: 15890310
[TBL] [Abstract][Full Text] [Related]
57. Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors.
Ozao-Choy J; Buch K; Strauchen JA; Warner RR; Divino CM
J Surg Res; 2010 Jul; 162(1):22-5. PubMed ID: 20421108
[TBL] [Abstract][Full Text] [Related]
58. Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors.
Gregersen T; Grønbæk H; Worsøe J; Schlageter V; Laurberg S; Krogh K
Scand J Gastroenterol; 2011 Jul; 46(7-8):895-902. PubMed ID: 21623673
[TBL] [Abstract][Full Text] [Related]
59. Gastric carcinoid type I tumour: new diagnostic and therapeutic method.
Prommegger R; Bale R; Ensinger C; Sauper T; Profanter C; Knoflach M; Moncayo R
Eur J Gastroenterol Hepatol; 2003 Jun; 15(6):705-7. PubMed ID: 12840685
[No Abstract] [Full Text] [Related]
60. Extended octreotide suppression test to determine hormone responsiveness of multiple type I gastric carcinoid tumors.
Fayyaz M; Mehboob S; Andersen V; Sitrin MD
Dig Dis Sci; 2007 Jun; 52(6):1579-85. PubMed ID: 17429721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
